This year’s American Society of Hematology (ASH) 2011 took place Saturday, December, 10, through yesterday in San Diego. This article summarizes the myelodysplastic syndromes-related highlights from Monday and yesterday.
Day 3
Monday was a busy day in terms of presentations related to myelodysplastic syndromes (MDS). There were several sessions with oral presentations throughout the day and a poster session in the evening.
The day began with a session about genetic alterations in MDS. During the session, researchers presented the latest findings on how alterations in patients’ genes and proteins may…
Results of an analysis show that early stem cell transplantation with reduced-intensity chemotherapy provides a survival benefit for older patients with higher-risk myelodysplastic syndromes, but not for those with lower-risk disease.
The study authors concluded that early transplantation is not an appropriate treatment strategy for older, lower-risk patients unless quality of life is significantly impaired.
The findings were presented at the 2011 American Society of Hematology (ASH) annual meeting in San Diego on Sunday.
Donor stem cell transplantation is currently the only available cure for myelodysplastic syndromes (MDS). Patients undergo chemotherapy…
The American Society of Hematology (ASH) 2011 annual meeting is currently being held in San Diego. This article will summarize the myelodysplastic syndromes-related highlights from Saturday, the first full day of the conference, and Sunday, the second day of the meeting.
Day 1
Saturday started off with an education session on myelodysplastic syndromes (MDS) that consisted of three talks. The program was repeated in the afternoon.
The day ended with a large poster session, during which study results from hundreds of blood disorder-related studies were displayed on big posters…
In this edition of his quarterly column, Dr. Steensma answers the question, Where does the name myelodysplastic syndromes come from? The column will be published as a two-part series. In Part 1, Dr. Steensma described the history of the disease name. In Part 2 (below), he addresses the origins of the name.
So what is the etymology (word history) of “myelodysplastic syndromes?”
To begin with, “myelo-“ has as its origin the Greek word μυελός, meaning “marrow.” Interestingly, there are also a number of terms related to the spinal cord…
The American Society of Hematology will hold its 53rd annual meeting this Saturday, December 10, through Tuesday, December 13, in San Diego.
Medical professionals will gather during the four-day meeting to discuss the latest findings for various blood diseases, including myelodysplastic syndromes (MDS).
The American Society of Hematology (ASH) meeting includes education and scientific sessions, poster viewings, and oral presentations, as well as meet-the-expert opportunities.
The latest MDS research findings will be discussed in over 50 oral presentations and more than 170 posters. In addition, the meeting features six education…